39 articles in this topic
Wave Life Sciences shares early trial data on an RNA editing treatment for alpha-1 antitrypsin deficiency, targeting monthly dosing.
A second wave of RAS-targeting therapies is reshaping cancer treatment, with implications for longevity through better tumor control.
AstraZeneca's baxdrostat wins FDA approval for hypertension, offering a novel mechanism for patients uncontrolled on existing therapies.
BIIB080 failed its primary endpoint in Phase 2, yet Biogen sees potential signals worth pursuing in the fight against Alzheimer's tau tangles.
Tumor-infiltrating lymphocyte therapies are emerging as a powerful cancer treatment. Here's what the science says and why it matters for longevity.
Eli Lilly suggests lower doses of tirzepatide may safely sustain weight loss at potentially lower cost, opening new options for long-term obesity management.
Astellas reports encouraging early-stage results for a stem cell-derived treatment targeting age-related eye disease, though data remains limited.
New wearable and non-invasive glucose monitors are transforming diabetes care — here's what's available and how they work.
Amgen expands late-stage testing of its long-acting obesity drug MariTide, including a trial for patients switching from rival GLP-1 medications.
A redesigned CRISPR system targets the chromosomal root cause of Down syndrome, opening new doors for genetic disease intervention.
Epicrispr's GEMS platform silences disease genes epigenetically — reversibly and safely — with a single viral vector, targeting FSHD and beyond.
Next-gen CAR-T approaches skip the lab and engineer immune cells directly inside the body, potentially making cancer therapy faster and cheaper.
